Abstract 996P
Background
For unresectable hepatocellular carcinoma (uHCC), the efficacy of transarterial chemoembolization (TACE) monotherapy is not satisfactory. Some studies have shown that TACE combined with molecular targeted drugs and programmed death-1 (PD-1) inhibitors shows potential synergistic effects that can prolong the overall survival (OS) of patients with uHCC. Donafenib is a new generation of multi-kinase inhibitor which is approved as the first line treatment for uHCC. This study aimed to evaluate the efficacy and safety of TACE combined with donafenib plus PD-1 inhibitor (TACE+DP) and of TACE combined with donafenib (TACE+D) for uHCC in a multicenter retrospective study.
Methods
The clinical data of patients with uHCC who had received TACE+DP or TACE+D as first-line treatment from six Chinese academic centers, from July 2021 to July 2022, were collected and retrospectively analyzed. In the TACE+DP group, patients received intravenous administration of PD-1 inhibitor every three weeks and oral donafenib (0.2 g) twice daily until intolerable toxicity or disease progression. In the TACE+D group, patients received the same dose of donafenib 3-5 days after TACE. Overall survival (OS), progression-free survival (PFS), and tumor responses were evaluated between the two groups according to the modified RECIST criteria.
Results
A total of 157 patients in the TACE+D group and 166 patients in TACE+DP group were included in this study. Patients in the TACE+DP group had longer median OS (18.1 vs 13.2 months, P<0.001) and longer median PFS (10.6 vs 7.9 months, P<0.001) than those in the TACE+D group. Patients in the TACE+DP group achieved a higher ORR (50.6% vs 41.4%, P=0.019) and a higher disease control rate (DCR) (89.2% vs 82.8%, P=0.010) than those in the TACE+D group. There was no significant difference in the incidence and severity of adverse events in the TACE+DP and TACE+D groups (any grade, 92.9% vs. 94.6%, P=0.270; grade 3 or 4, 33.8% vs. 37.3%, P=0.253).
Conclusions
With favorable safety and tolerability, TACE combined donafenib with PD-1 inhibitors significantly improves PFS, OS, and ORR over TACE combined with donafenib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital of Zhengzhou University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18